News & Updates
Filter by Specialty:

Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
Treatment-naive patients with immediate-risk (IR) nonmuscle-invasive bladder cancer (NMIBC) who received gemcitabine appear to have greater recurrence risk than those given Bacillus Calmette-Guerin (BCG). Both treatments, however, are effective against disease progression.
Gemcitabine for IR-NMIBC tied to more recurrence vs BCG
06 Jun 2025
Nerve-sparing technique preserves erectile function after RARP
A nerve-sparing technique decreases erectile dysfunction in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer in a phase III study.
Nerve-sparing technique preserves erectile function after RARP
13 May 2025
Rectal spacer relieves GI issues following RT for prostate cancer
In a large retrospective study, the incidence of bowel disorders and related procedures dropped when a polyethylene glycol-based hydrogel spacer (PHS) was used in men undergoing radiotherapy (RT) for prostate cancer.
Rectal spacer relieves GI issues following RT for prostate cancer
08 May 2025
LHRH analogues vs tE2 patches: Which work best for prostate cancer?
The use of transdermal oestradiol (tE2) or oestrogen patches helps suppress testosterone and prostate-specific antigen (PSA) in men with locally advanced prostate cancer, with similar efficacy to that of luteinizing hormone-releasing hormone (LHRH) analogues, reports a study presented at EAU 2025.
LHRH analogues vs tE2 patches: Which work best for prostate cancer?
02 May 2025
Self-efficacy high among survivors of prostate cancer
Long-term prostate cancer survivors report high levels of self-efficacy, but the contrary is true for subgroups who are facing some challenges, a study presented at EAU 2025 has found.
Self-efficacy high among survivors of prostate cancer
01 May 2025
Proteomic analysis identifies DKD progression markers in YT2D
A comprehensive analysis of circulating proteins identifies known and novel proteins associated with the progression of diabetic kidney disease (DKD) in Asians with younger-onset type 2 diabetes (YT2D; T2D onset age <40 years).